Research

Decoding biological information encoded through the molecular organization of receptors.

Our research programs focus on developing a quantitative map of signaling receptor organization in space and time across cells, organoids, and tissues. We develop and utilize state-of-the-art imaging tools for addressing our scientific questions.

01

Dynamic organization of signaling clusters and nanodomains

Quantitative molecular mapping of how receptors organize and distribute on the cell surface. We are primarily interested in the spatiotemporal (re)organization of receptor molecules on the membrane of (CAR) T cells, B cells, and tumor cells. The overarching goal is to decipher how stoichiometry, receptor clustering, and mobility vary with signaling state and their roles in immune signaling fate. A second area of exploration is receptorome organization in cardiomyocytes and its role in heart failure.

02

Cell-cell junction nanoarchitecture

We are deeply interested in resolving the 3D molecular architecture of intercellular junctions, from CAR T cell-based immune synapses to gap junctions, and to understand the role of local membrane organization in regulating cell-cell communication.

03

Tumor microenvironment

Beyond cell-cell interactions, we aim to upscale our investigations on receptor organization and dynamics at the organoid and tissue scales, to uncover how spatial signaling patterns shape immunotherapeutic response.

04

Aiding the design of next-gen immunotherapies

We are particularly interested in decoding how therapeutic antibodies, antibody-drug conjugates, and CAR T cells used in hematological malignancies function at the molecular level. Key questions include how antibody binding and receptor crosslinking elicit cytotoxic response, dissecting the dynamic organization of CAR siganalosome on T cell surface and at the synapse, etc. Developing a holistic understanding of receptor spatiotemporal organization and correlated efficacy of currently approved therapies, our findings will provide entirely new molecular-scale insights, thus helping clinicians to design refined therapies.